Published in MedGenMed on May 31, 2006
Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med (2002) 12.95
Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med (2004) 7.12
Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med (2004) 6.55
Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet (1997) 6.48
The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med (2001) 5.50
Plasma B-type natriuretic peptide levels in ambulatory patients with established chronic symptomatic systolic heart failure. Circulation (2003) 4.25
The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol (2005) 3.85
N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med (2005) 3.35
Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation (2002) 2.86
B-type natriuretic peptide and ischemia in patients with stable coronary disease: data from the Heart and Soul study. Circulation (2003) 2.82
Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension (1996) 2.37
Prognostic value of serial B-type natriuretic peptide testing during follow-up of patients with unstable coronary artery disease. JAMA (2005) 2.17
Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure. Proc Natl Acad Sci U S A (2005) 1.85
Acute changes in circulating natriuretic peptide levels in relation to myocardial ischemia. J Am Coll Cardiol (2004) 1.70
Cardiac natriuretic peptides for diagnosis and risk stratification in heart failure: influences of left ventricular dysfunction and coronary artery disease on cardiac hormonal activation. Eur J Clin Invest (1998) 1.60
The relationship between B-type natriuretic peptide and health status in patients with heart failure. J Card Fail (2005) 1.58
B-type natriuretic peptide levels are not a surrogate marker for invasive hemodynamics during management of patients with severe heart failure. Am Heart J (2005) 1.51
B-type natriuretic peptide levels: a potential novel "white count" for congestive heart failure. J Card Fail (2001) 1.29
Plasma A- and B-type natriuretic peptides: physiology, methodology and clinical use. Cardiovasc Res (2001) 1.14
Incremental prognostic value of changes in B-type natriuretic peptide in heart failure. Am J Med (2006) 1.03
Measuring plasma B-type natriuretic peptide in heart failure: good to go in 2004? J Am Coll Cardiol (2004) 0.98
Pathophysiologic relevance of measuring the plasma levels of cardiac natriuretic peptide hormones in humans. Horm Metab Res (1999) 0.97
Differential expression of cardiac ANP and BNP in a rabbit model of progressive left ventricular dysfunction. Cardiovasc Res (2001) 0.96
Performance characteristics of four automated natriuretic peptide assays. Am J Clin Pathol (2005) 0.93
Circulating levels of cardiac natriuretic peptides (ANP and BNP) measured by highly sensitive and specific immunoradiometric assays in normal subjects and in patients with different degrees of heart failure. J Endocrinol Invest (1998) 0.93
Antihypertensive effect of a 5-day infusion of atrial natriuretic factor in humans. Hypertension (1989) 0.84
Blood volume and brain natriuretic peptide in congestive heart failure: a pilot study. Am Heart J (2005) 0.83
Optimum blood collection intervals for B-type natriuretic peptide testing in patients with heart failure. Am J Cardiol (2004) 0.80
Harmonization of the Bayer ADVIA Centaur and Abbott AxSYM automated B-type natriuretic peptide assay in patients on hemodialysis. Clin Chem Lab Med (2005) 0.77
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature (2011) 13.53
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet (2011) 13.25
2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2013) 11.88
2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation (2013) 10.07
Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med (2013) 9.44
HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail (2010) 6.37
Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol (2009) 5.76
Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction. N Engl J Med (2015) 4.39
2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation (2013) 3.86
New gene functions in megakaryopoiesis and platelet formation. Nature (2011) 3.14
Genome-wide association study of coronary heart disease and its risk factors in 8,090 African Americans: the NHLBI CARe Project. PLoS Genet (2011) 3.07
Seventy-five genetic loci influencing the human red blood cell. Nature (2012) 2.77
Cardiorenal outcomes after slow continuous ultrafiltration therapy in refractory patients with advanced decompensated heart failure. J Am Coll Cardiol (2012) 2.75
Spironolactone in chronic heart failure:all's well that ends well. J Am Coll Cardiol (2003) 2.47
Sodium nitroprusside for advanced low-output heart failure. J Am Coll Cardiol (2008) 2.47
Diabetic cardiomyopathy: insights into pathogenesis, diagnostic challenges, and therapeutic options. Am J Med (2008) 2.42
Delayed hyper-enhancement magnetic resonance imaging provides incremental diagnostic and prognostic utility in suspected cardiac amyloidosis. JACC Cardiovasc Imaging (2009) 2.41
Response to cardiac resynchronization therapy in elderly patients (≥70 years) and octogenarians. Eur J Heart Fail (2012) 2.21
Prognostic value of choline and betaine depends on intestinal microbiota-generated metabolite trimethylamine-N-oxide. Eur Heart J (2014) 2.08
Hypoxia-inducible factors in human pulmonary arterial hypertension: a link to the intrinsic myeloid abnormalities. Blood (2011) 2.08
High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circ Heart Fail (2010) 1.96
Detection of soluble angiotensin-converting enzyme 2 in heart failure: insights into the endogenous counter-regulatory pathway of the renin-angiotensin-aldosterone system. J Am Coll Cardiol (2008) 1.95
Elevated intra-abdominal pressure in acute decompensated heart failure: a potential contributor to worsening renal function? J Am Coll Cardiol (2008) 1.87
Insights from a cardiac resynchronization optimization clinic as part of a heart failure disease management program. J Am Coll Cardiol (2009) 1.86
Role of the CHADS2 score in the evaluation of thromboembolic risk in patients with atrial fibrillation undergoing transesophageal echocardiography before pulmonary vein isolation. J Am Coll Cardiol (2009) 1.78
Serum neutrophil gelatinase-associated lipocalin (NGAL) in predicting worsening renal function in acute decompensated heart failure. J Card Fail (2009) 1.75
Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst (2010) 1.73
Pulmonary hypertension associated with advanced systolic heart failure: dysregulated arginine metabolism and importance of compensatory dimethylarginine dimethylaminohydrolase-1. J Am Coll Cardiol (2012) 1.69
Persistent hemodynamic benefits of cardiac resynchronization therapy with disease progression in advanced heart failure. J Am Coll Cardiol (2009) 1.64
Cardiac troponins in renal insufficiency: review and clinical implications. J Am Coll Cardiol (2002) 1.63
The contributory role of gut microbiota in cardiovascular disease. J Clin Invest (2014) 1.57
Early and late effects of cardiac resynchronization therapy on force-frequency relation and contractility regulating gene expression in heart failure patients. Heart Rhythm (2007) 1.57
Association of a genetic risk score with prevalent and incident myocardial infarction in subjects undergoing coronary angiography. Circ Cardiovasc Genet (2012) 1.54
Images in cardiovascular medicine. Tako-tsubo--like transient left ventricular dysfunction. Circulation (2003) 1.52
Time from emerging heart failure symptoms to cardiac resynchronisation therapy: impact on clinical response. Heart (2012) 1.45
The impact of left ventricular size on response to cardiac resynchronization therapy. Am Heart J (2011) 1.45
Targeted metabolomic evaluation of arginine methylation and cardiovascular risks: potential mechanisms beyond nitric oxide synthase inhibition. Arterioscler Thromb Vasc Biol (2009) 1.44
Immunoglobulins against tyrosine-nitrated epitopes in coronary artery disease. Circulation (2012) 1.42
QRS prolongation induced by cardiac resynchronization therapy correlates with deterioration in left ventricular function. Heart Rhythm (2012) 1.42
Potential effects of digoxin on long-term renal and clinical outcomes in chronic heart failure. J Card Fail (2013) 1.41
Pulmonary vascular response to exercise in symptomatic heart failure with reduced ejection fraction and pulmonary hypertension. Eur J Heart Fail (2014) 1.40
Dexamethasone, light anaesthesia, and tight glucose control (DeLiT) randomized controlled trial. Br J Anaesth (2013) 1.39
National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: Clinical utilization of cardiac biomarker testing in heart failure. Circulation (2007) 1.39
Incremental prognostic value of assessing left ventricular myocardial mechanics in patients with chronic systolic heart failure. J Am Coll Cardiol (2012) 1.37
A genome-wide association study for coronary artery disease identifies a novel susceptibility locus in the major histocompatibility complex. Circ Cardiovasc Genet (2012) 1.35
Ventricular geometry, strain, and rotational mechanics in pulmonary hypertension. Circulation (2010) 1.34
Improved prediction of cardiovascular disease based on a panel of single nucleotide polymorphisms identified through genome-wide association studies. Circ Cardiovasc Genet (2010) 1.23
Protein carbamylation predicts mortality in ESRD. J Am Soc Nephrol (2013) 1.22
Myeloperoxidase, paraoxonase-1, and HDL form a functional ternary complex. J Clin Invest (2013) 1.21
Loop diuretic efficiency: a metric of diuretic responsiveness with prognostic importance in acute decompensated heart failure. Circ Heart Fail (2013) 1.19
Research priorities in hypertrophic cardiomyopathy: report of a Working Group of the National Heart, Lung, and Blood Institute. Circulation (2010) 1.18
Lipoprotein(a) levels and long-term cardiovascular risk in the contemporary era of statin therapy. J Lipid Res (2010) 1.18
Plasma B-type natriuretic peptide levels predict postoperative atrial fibrillation in patients undergoing cardiac surgery. Circulation (2004) 1.17
Differential response to cardiac resynchronization therapy and clinical outcomes according to QRS morphology and QRS duration. J Am Coll Cardiol (2012) 1.15
Right atrial volume index in chronic systolic heart failure and prognosis. JACC Cardiovasc Imaging (2009) 1.12
Fasting 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography to detect metabolic changes in pulmonary arterial hypertension hearts over 1 year. Ann Am Thorac Soc (2013) 1.11
Timing of hemoconcentration during treatment of acute decompensated heart failure and subsequent survival: importance of sustained decongestion. J Am Coll Cardiol (2013) 1.10
Lack of significant renal tubular injury despite acute kidney injury in acute decompensated heart failure. Eur J Heart Fail (2012) 1.10
Abdominal contributions to cardiorenal dysfunction in congestive heart failure. J Am Coll Cardiol (2013) 1.10
Comparative genome-wide association studies in mice and humans for trimethylamine N-oxide, a proatherogenic metabolite of choline and L-carnitine. Arterioscler Thromb Vasc Biol (2014) 1.08
Relation of systemic and urinary neutrophil gelatinase-associated lipocalin levels to different aspects of impaired renal function in patients with acute decompensated heart failure. Am J Cardiol (2012) 1.08
Cardiac troponins in renal insufficiency and other non-ischemic cardiac conditions. Prog Cardiovasc Dis (2005) 1.07
Insulin resistance in idiopathic dilated cardiomyopathy: a possible etiologic link. J Am Coll Cardiol (2004) 1.06
Prognostic role of pulmonary arterial capacitance in advanced heart failure. Circ Heart Fail (2012) 1.06
Right ventricular response to intensive medical therapy in advanced decompensated heart failure. Circ Heart Fail (2010) 1.06
Changes in intrathoracic impedance are associated with subsequent risk of hospitalizations for acute decompensated heart failure: clinical utility of implanted device monitoring without a patient alert. J Card Fail (2009) 1.05
Acute decompensated heart failure: update on new and emerging evidence and directions for future research. J Card Fail (2013) 1.04
Soluble angiotensin-converting enzyme 2 in human heart failure: relation with myocardial function and clinical outcomes. J Card Fail (2009) 1.04
Indications for cardiac resynchronization therapy: 2011 update from the Heart Failure Society of America Guideline Committee. J Card Fail (2012) 1.02
Association between the chromosome 9p21 locus and angiographic coronary artery disease burden: a collaborative meta-analysis. J Am Coll Cardiol (2013) 1.02
Long-term reverse remodeling with cardiac resynchronization therapy: results of extended echocardiographic follow-up. J Am Coll Cardiol (2010) 1.00
National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine practice guidelines: Analytical issues for biomarkers of heart failure. Circulation (2007) 1.00
Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. Heart Failure Society of America Guidelines Committee. J Card Fail (2012) 1.00
CD36 and Na/K-ATPase-α1 form a proinflammatory signaling loop in kidney. Hypertension (2012) 0.99
Choline Diet and Its Gut Microbe-Derived Metabolite, Trimethylamine N-Oxide, Exacerbate Pressure Overload-Induced Heart Failure. Circ Heart Fail (2015) 0.99
Usefulness of Isosorbide Dinitrate and Hydralazine as add-on therapy in patients discharged for advanced decompensated heart failure. Am J Cardiol (2009) 0.99
Site-specific nitration of apolipoprotein A-I at tyrosine 166 is both abundant within human atherosclerotic plaque and dysfunctional. J Biol Chem (2014) 0.98
Cystatin C identifies patients with stable chronic heart failure at increased risk for adverse cardiovascular events. Circ Heart Fail (2012) 0.97
Renal dysfunction is a stronger determinant of systemic neutrophil gelatinase-associated lipocalin levels than myocardial dysfunction in systolic heart failure. J Card Fail (2011) 0.97
Genetic contribution of the leukotriene pathway to coronary artery disease. Hum Genet (2011) 0.96
Function and distribution of apolipoprotein A1 in the artery wall are markedly distinct from those in plasma. Circulation (2013) 0.96
Determinants of dynamic changes in serum creatinine in acute decompensated heart failure: the importance of blood pressure reduction during treatment. Eur J Heart Fail (2013) 0.95
Single exhaled breath metabolomic analysis identifies unique breathprint in patients with acute decompensated heart failure. J Am Coll Cardiol (2013) 0.94
Isolated left ventricular non-compaction controversies in diagnostic criteria, adverse outcomes and management. Heart (2012) 0.94
Cardiac resynchronization therapy in CKD: a systematic review. Clin J Am Soc Nephrol (2013) 0.93
Prognostic evaluation of ambulatory patients with advanced heart failure. Am J Cardiol (2008) 0.93
Diminished antioxidant activity of high-density lipoprotein-associated proteins in chronic kidney disease. J Am Heart Assoc (2013) 0.93
The transcription factor GATA-2 does not associate with angiographic coronary artery disease in the Ottawa Heart Genomics and Cleveland Clinic GeneBank Studies. Hum Genet (2009) 0.92
Risk prediction with serial myeloperoxidase monitoring in patients with acute chest pain. Clin Chem (2011) 0.92
Prompt reduction in intra-abdominal pressure following large-volume mechanical fluid removal improves renal insufficiency in refractory decompensated heart failure. J Card Fail (2008) 0.92
Translating metabolomics to cardiovascular biomarkers. Prog Cardiovasc Dis (2012) 0.92
Increased exhaled nitric oxide levels after exercise in patients with chronic systolic heart failure with pulmonary venous hypertension. J Card Fail (2012) 0.92
Device monitoring strategies in acute heart failure syndromes. Heart Fail Rev (2011) 0.91
The chromosome 9p21.3 coronary heart disease risk allele is associated with altered gene expression in normal heart and vascular tissues. PLoS One (2012) 0.91
Patterns of beta-blocker utilization in patients with chronic heart failure: experience from a specialized outpatient heart failure clinic. Am Heart J (2004) 0.91
Role of imaging in the diagnosis and management of patients with cardiac amyloidosis: state of the art review and focus on emerging nuclear techniques. J Nucl Cardiol (2014) 0.90
Prognostic value of cardiac troponin in chronic stable heart failure: a systematic review. Heart (2012) 0.90
Pharmacologic strategies to target oxidative stress in heart failure. Curr Heart Fail Rep (2012) 0.90
Comprehensive peroxidase-based hematologic profiling for the prediction of 1-year myocardial infarction and death. Circulation (2010) 0.90